CHENNAI: The Chennai-based pharma major, Orchid Chemicals announced on Tuesday that it has received the formal approval from the USFDA for its ANDA (abbreviated new drug application) for Cefprozil for Oral Suspension USP, 125 mg/5 ml and 250 mg/5 ml. Cefprozil is the generic version of Bristol-Myers Squibb's broad-spectrum cephalosporin antibiotic Cefzil. The current U.S. market size for Cefprozil oral suspension is $120 million. Orchid is launching the product in the U.S. exclusively through its marketing alliance partner, Par Pharmaceuticals.